Higher Circulating Levels of Chemokine CCL20 in Patients with Multiple Sclerosis: Evaluation of the Influences of Chemokine Gene Polymorphism, Gender, Treatment and Disease Pattern

被引:39
作者
Jafarzadeh, A. [1 ,2 ,3 ]
Bagherzadeh, S. [2 ]
Ebrahimi, H. A. [1 ]
Hajghani, H. [2 ]
Bazrafshani, M. R. [4 ]
Khosravimashizi, A. [2 ]
Nemati, M. [2 ]
Gadari, F. [1 ]
Sabahi, A. [1 ]
Iranmanesh, F. [1 ]
Mohammadi, M. M. [2 ]
Daneshvar, H. [2 ]
机构
[1] Kerman Univ Med Sci, Dept Neurol, Neurol Res Ctr, Kerman, Iran
[2] Kerman Univ Med Sci, Sch Med, Dept Immunol, Kerman, Iran
[3] Rafsanjan Univ Med Sci, Sch Med, Dept Immunol, Rafsanjan, Iran
[4] Kerman Univ Med Sci, Sch Med, Dept Med Genet, Kerman, Iran
关键词
Multiple sclerosis; CCL20; Gene polymorphism; Treatment; TH17; CELLS; METHYLPREDNISOLONE; PATHOGENESIS; ASTROCYTES; ROLES; IL-17; CNS;
D O I
10.1007/s12031-013-0214-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Chemokines play an important role in the autoimmune diseases. The aim of this study was to investigate the levels of CCL20 and a polymorphism [-786C > T (rs6749704)] in the chemokine gene in patients with multiple sclerosis (MS). The blood samples were collected from 135 MS patients and 135 healthy subjects as a control group. The patients have relapsing-remitting (RRMS; n = 65), primary progressive (PPMS; n = 47), secondary progressive (SPMS; n = 35) or progressive relapsing (PRMS; n = 14) patterns. The serum levels of CCL20 were measured by ELISA. The DNA was analyzed for CCL20 polymorphism using PCR-RLFP. The mean serum levels of CCL20 in the MS group were significantly higher than in the healthy group (P < 0.001). In patients with a SPMS pattern, the frequency of CT genotype at rs6749704 (24.3 %) was significantly lower as compared to patients with other patterns (42.8 %; P < 0.04). No significant differences were observed between subjects with different genotypes in rs6749704 regarding the CCL20 levels. The mean serum levels of CCL20 in both newly diagnosed and previously diagnosed patients was significantly higher than in the healthy group (P < 0.05 and 0.001, respectively). The mean serum levels of CCL20 in patients with RRMS, SPMS and PPMS patterns were significantly higher than in the healthy group (P < 0.004, P < 0.04, and 0.05, respectively). The levels of CCL20 in untreated patients and in patients who received interferon-beta, methylprednisolone or the combination of interferon-beta plus methylprednisolone were higher as compared to the control group (P < 0.05, P < 0.03, P < 0.005, and P < 0.05, respectively). These results showed higher levels of CCL20 in patients that represent that the chemokine may play an important role in the pathogenesis of MS. The rs6749704 polymorphism was an associated SPMS pattern. The levels of CCL20 were not influenced by gender, disease pattern and treatment.
引用
收藏
页码:500 / 505
页数:6
相关论文
共 25 条
[1]   Astrocytes are the major intracerebral source of macrophage inflammatory protein-3α/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro [J].
Ambrosini, E ;
Columba-Cabezas, S ;
Serafini, B ;
Muscella, A ;
Aloisi, F .
GLIA, 2003, 41 (03) :290-300
[2]  
Anlar O, 2009, CNS NEUROL DISORD-DR, V8, P167
[3]   Role of Regulatory T Cells in Pathogenesis and Biological Therapy of Multiple Sclerosis [J].
Buc, Milan .
MEDIATORS OF INFLAMMATION, 2013, 2013
[4]   Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17-and Activated B-Cells and Correlates with Progression [J].
Christensen, Jeppe Romme ;
Bornsen, Lars ;
Ratzer, Rikke ;
Piehl, Fredrik ;
Khademi, Mohsen ;
Olsson, Tomas ;
Sorensen, Per Soelberg ;
Sellebjerg, Finn .
PLOS ONE, 2013, 8 (03)
[5]   A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA) [J].
Hoglund, Rune A. ;
Holmoy, Trygve ;
Harbo, Hanne F. ;
Maghazachi, Azzam A. .
PLOS ONE, 2013, 8 (04)
[6]   The blood-brain barrier, chemokines and multiple sclerosis [J].
Holman, David W. ;
Klein, Robyn S. ;
Ransohoff, Richard M. .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2011, 1812 (02) :220-230
[7]   Th17 Cell, the New Player of Neuroinflammatory Process in Multiple Sclerosis [J].
Jadidi-Niaragh, F. ;
Mirshafiey, A. .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2011, 74 (01) :1-13
[8]   Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing remitting multiple sclerosis patients [J].
Kalinowska-Lyszczarz, Alicja ;
Szczucinski, Adam ;
Pawlak, Mikolaj A. ;
Losy, Jacek .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 300 (1-2) :81-85
[9]   Cytokine profile in relapsing-remitting multiple sclerosis patients and the association between progression and activity of the disease [J].
Kallaur, Ana Paula ;
Oliveira, Sayonara Rangel ;
Colado Simao, Andrea Name ;
Delicato De Almeida, Elaine Regina ;
Morimoto, Helena Kaminami ;
Lopes, Josiane ;
De Carvalho Jennings Pereira, Wildea Lice ;
Andrade, Renato Marques ;
Pelegrino, Larissa Muliterno ;
Borelli, Sueli Donizete ;
Kaimen-Maciel, Damacio Ramon ;
Vissoci Reiche, Edna Maria .
MOLECULAR MEDICINE REPORTS, 2013, 7 (03) :1010-1020
[10]   Emerging new roles of Th17 cells [J].
Kuchroo, Vijay K. ;
Awasthi, Amit .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2012, 42 (09) :2211-2214